165 related articles for article (PubMed ID: 28346525)
1. Modeling timelines for translational science in cancer; the impact of technological maturation.
McNamee LM; Ledley FD
PLoS One; 2017; 12(3):e0174538. PubMed ID: 28346525
[TBL] [Abstract][Full Text] [Related]
2. Patterns of Innovation in Alzheimer's Disease Drug Development: A Strategic Assessment Based on Technological Maturity.
Beierlein JM; McNamee LM; Walsh MJ; Ledley FD
Clin Ther; 2015 Aug; 37(8):1643-51.e3. PubMed ID: 26243074
[TBL] [Abstract][Full Text] [Related]
3. Timelines of translational science: From technology initiation to FDA approval.
McNamee LM; Walsh MJ; Ledley FD
PLoS One; 2017; 12(5):e0177371. PubMed ID: 28481922
[TBL] [Abstract][Full Text] [Related]
4. Landscape of Innovation for Cardiovascular Pharmaceuticals: From Basic Science to New Molecular Entities.
Beierlein JM; McNamee LM; Walsh MJ; Kaitin KI; DiMasi JA; Ledley FD
Clin Ther; 2017 Jul; 39(7):1409-1425.e20. PubMed ID: 28652015
[TBL] [Abstract][Full Text] [Related]
5. Translational science by public biotechnology companies in the IPO "class of 2000": the impact of technological maturity.
McNamee L; Ledley F
PLoS One; 2013; 8(12):e82195. PubMed ID: 24358154
[TBL] [Abstract][Full Text] [Related]
6. The changing environment for technological innovation in health care.
Goodman CS; Gelijns AC
Baxter Health Policy Rev; 1996; 2():267-315. PubMed ID: 11066263
[TBL] [Abstract][Full Text] [Related]
7. Mapping knowledge translation and innovation processes in Cancer Drug Development: the case of liposomal doxorubicin.
Fajardo-Ortiz D; Duran L; Moreno L; Ochoa H; Castaño VM
J Transl Med; 2014 Sep; 12():227. PubMed ID: 25182125
[TBL] [Abstract][Full Text] [Related]
8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
9. Perspective: Transforming science into medicine: how clinician-scientists can build bridges across research's "valley of death".
Roberts SF; Fischhoff MA; Sakowski SA; Feldman EL
Acad Med; 2012 Mar; 87(3):266-70. PubMed ID: 22373616
[TBL] [Abstract][Full Text] [Related]
10. As Technologies for Nucleotide Therapeutics Mature, Products Emerge.
Beierlein JM; McNamee LM; Ledley FD
Mol Ther Nucleic Acids; 2017 Dec; 9():379-386. PubMed ID: 29246316
[TBL] [Abstract][Full Text] [Related]
11. Catalysts for Change: The Role of Small Business Funders in the Creation and Dissemination of Innovation.
Shic F; Smith D; Horsburgh B; Hollander E; Rehg JM; Goodwin M
J Autism Dev Disord; 2015 Dec; 45(12):3900-4. PubMed ID: 26481385
[TBL] [Abstract][Full Text] [Related]
12. Why commercialization of gene therapy stalled; examining the life cycles of gene therapy technologies.
Ledley FD; McNamee LM; Uzdil V; Morgan IW
Gene Ther; 2014 Feb; 21(2):188-94. PubMed ID: 24305420
[TBL] [Abstract][Full Text] [Related]
13. Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.
Venkatakrishnan K; Friberg LE; Ouellet D; Mettetal JT; Stein A; Trocóniz IF; Bruno R; Mehrotra N; Gobburu J; Mould DR
Clin Pharmacol Ther; 2015 Jan; 97(1):37-54. PubMed ID: 25670382
[TBL] [Abstract][Full Text] [Related]
14. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
15. Thyroid cancer: are molecular studies making any difference?
Kim DS
J Laryngol Otol; 2007 Oct; 121(10):917-26. PubMed ID: 17592664
[TBL] [Abstract][Full Text] [Related]
16. Designing transformative clinical trials in the cancer genome era.
Sleijfer S; Bogaerts J; Siu LL
J Clin Oncol; 2013 May; 31(15):1834-41. PubMed ID: 23589555
[TBL] [Abstract][Full Text] [Related]
17. Targeting cancer with hyaluronic acid-based nanocarriers: recent advances and translational perspectives.
Cadete A; Alonso MJ
Nanomedicine (Lond); 2016 Sep; 11(17):2341-57. PubMed ID: 27526874
[TBL] [Abstract][Full Text] [Related]
18. Translating Trial Results in Clinical Practice: the Risk GP Model.
Fuller J; Flores LJ
J Cardiovasc Transl Res; 2016 Jun; 9(3):167-168. PubMed ID: 27146316
[No Abstract] [Full Text] [Related]
19. Lessons Learned from Two Decades of Anticancer Drugs.
Liu Z; Delavan B; Roberts R; Tong W
Trends Pharmacol Sci; 2017 Oct; 38(10):852-872. PubMed ID: 28709554
[TBL] [Abstract][Full Text] [Related]
20. [Focus on innovation in and translation of basic research in ophthalmology].
Xu X
Zhonghua Yan Ke Za Zhi; 2012 Jul; 48(7):581-2. PubMed ID: 22943859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
